Supply Agreement

• Parties: Centre for Probe Development and Commercialization ("CPDC"), FUSION Pharmaceuticals Inc. ("FUSION"), (together "Parties", each a "Party")
• Renewal Term: successive 1 year
• Section: Commercial Contracts

Exhibit 10.17

Supply Agreement - FUSION

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED

INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE

HARM TO THE COMPANY IF DISCLOSED.

SUPPLY AGREEMENT (“Supply Agreement”) effective as of the date of last signing (“Effective Date”) between Centre for Probe Development and

Commercialization, a not-for-profit research and services institution with offices located at McMaster University, Nuclear Research Building, 1280 Main

Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CPDC”), and FUSION Pharmaceuticals Inc. (“FUSION”), having a place of business at 270 Longwood

Road South, Hamilton, Ontario, Canada, L8P 0A6, (together the “Parties” each a “Party”). This document defines the terms and conditions under which

CPDC will provide FUSION the Product outlined in this Supply Agreement.

This Supply Agreement is conducted under the general provisions of the Master Services Agreement and the Quality Agreement entered into between

the PARTIES. Unless explicitly stated within this Supply Agreement should there be discrepancies between the Supply Agreement and the Master

Services Agreement, then the Master Services Agreement will be the controlling document.

1. “Products”:

1.1 Ac-225 FPI-1434

1.2 [***]

1.3 The specifications for the Products are further defined in Schedule 2.

2. Definitions

As used herein, the following terms shall have the following meanings:

2.1 Affiliate(s) shall exclude CPDC, when referring to FUSION’S affiliates, and shall exclude FUSION, when referring to CPDC’s affiliates.

2.2 “Batch” shall mean a single production, testing and release of Product according to the approved and validated processes.

2.3 “Clinical Phase” shall mean the period during which human studies involving the Products are performed for the purpose of evaluating the safety,

efficacy and appropriate dose ranges of Product (“Clinical Trials”), to secure marketing approval from a Regulatory Authority.

2.4 “Current Good Manufacturing Practices” or “cGMP(s)” shall mean the standards required by the Regulatory Authority for the manufacturing,

testing and quality control of pharmaceutical materials, which practices are current on the Effective Date of this Agreement and may be

supplemented, amended or modified by such regulatory authority from time to time.

2.5 “Date of Manufacturing” shall mean the date on which the drug product is produced.

2.6 “[***] Territory” shall mean the territories [***] for which CPDC shall be the [***] supplier of Products for Fusion.

2.7 “Master Services Agreement” the agreement executed between the Parties on the 21st day of February, 2017.

2.8 “Precursors” shall mean the starting materials required to produce Product. For the purpose of this agreement, the Precursors are defined as FPI-

1175 and [***].

Page 1 of 13 CONFIDENTIAL